Ensysce Biosciences
NASDAQ: ENSCLa Jolla, US · Delaware corporation
Ensysce is a pharmaceutical development company focused on developing safer medicines, with particular expertise in pain management and opioid-related drug development. The team has extensive experience bringing targeted small molecule drugs and oncology compounds from discovery through clinical development to market approval.
Founders & leadership
DL
D. Lynn Kirkpatrick, PhDCo-founder
DB
Dr. Bob GowerFounder and Chairman
JM
James MorrisonExecutive
DL
D. Lynn KirkpatrickinExecutive
DH
Dave HumphreyinExecutive
LP
Linda Pestano
LP
Linda Pestano, PhD
DW
Dr. William Schmidt, PhD
Board
AB
Andrew BentonBoard director
CR
Curtis RosebraughBoard director
WC
William ChangBoard director
SM
Steve MartinBoard director
Reported raises · per SEC filings
Form D private placements$102.6M disclosed across 8 rounds · 2021–2026
▶$77.2MraisedAug 2026 · 44 investors · Other Health CareRule 506(b)
▶$77.2MraisedAug 2026 · 44 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- D Lynn KirkpatrickExecutive Officer, Director
- Bob GowerDirector
- William ChangDirector
- Steve MartinDirector
- Adam LevinDirector
- David HumphreyExecutive Officer
- James MorrisonExecutive Officer, Director
- Offering amount
- $77.2M
- Amount sold
- $77.2M
- Sales commissions
- $1.3M
- Finders' fees
- $200K
- Placement agents
- UBS Securities LLC, Cantor Fitzgerald & Co.
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedApr 2025 · 8 investors · Other Health CareRule 506(b)
▶$2.2MraisedApr 2025 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- D Lynn KirkpatrickExecutive Officer, Director
- David HumphreyExecutive Officer
- Adam LevinDirector
- Curtis RosebraughDirector
- Lee RauchDirector
- William ChangDirector
- Andrew BentonDirector
- Steve MartinDirector
- Bob GowerDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- Sales commissions
- $154K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedApr 2025 · 8 investors · Other Health CareRule 506(b)
▶$1.1MraisedApr 2025 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Adam LevinDirector
- Lee RauchDirector
- D Lynn KirkpatrickExecutive Officer, Director
- Andrew BentonDirector
- David HumphreyExecutive Officer
- Curtis RosebraughDirector
- William ChangDirector
- Steve MartinDirector
- Bob GowerDirector
- Offering amount
- $1.1M
- Amount sold
- $1.1M
- Sales commissions
- $142.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedSep 2024 · 4 investors · Other Health CareRule 506(b)
▶$5.1MraisedSep 2024 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Andrew BentonDirector
- Curtis RosebraughDirector
- William ChangDirector
- Bob GowerDirector
- Steve MartinDirector
- David HumphreyExecutive Officer
- Adam LevinDirector
- Lee RauchDirector
- D Lynn KirkpatrickExecutive Officer, Director
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- Sales commissions
- $454.8K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.7MraisedFeb 2024 · 4 investors · Other Health CareRule 506(b)
▶$4.7MraisedFeb 2024 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Adam LevinDirector
- Lee RauchDirector
- Bob GowerDirector
- D Lynn KirkpatrickExecutive Officer, Director
- Andrew BentonDirector
- David HumphreyExecutive Officer
- Steve MartinDirector
- William ChangDirector
- Curtis RosebraughDirector
- Offering amount
- $4.7M
- Amount sold
- $4.7M
- Sales commissions
- $265.9K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.8MraisedMar 2023 · 8 investors · Other Health CareRule 506(b)
▶$2.8MraisedMar 2023 · 8 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bob GowerDirector
- Adam LevinDirector
- D Lynn KirkpatrickExecutive Officer, Director
- Steve MartinDirector
- David HumphreyExecutive Officer
- Andrew BentonDirector
- Curtis RosebraughDirector
- Lee RauchDirector
- William ChangDirector
- Offering amount
- $2.8M
- Amount sold
- $2.8M
- Sales commissions
- $210K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.2MraisedJul 2022 · 3 investors · Other Health CareRule 506(b)
▶$4.2MraisedJul 2022 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Bob GowerDirector
- D Lynn KirkpatrickExecutive Officer, Director
- Steve MartinDirector
- Curtis RosebraughDirector
- David HumphreyExecutive Officer
- William ChangDirector
- Lee RauchDirector
- Adam LevinDirector
- Andrew BentonDirector
- Offering amount
- $8.5M
- Amount sold
- $4.2M
- Finders' fees
- $200K
- Placement agents
- Lake Street Capital Markets, LLC
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.3MraisedOct 2021 · 3 investors · Other Health CareRule 506(b)
▶$5.3MraisedOct 2021 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- David HumphreyExecutive Officer
- Andrew BentonDirector
- D Lynn KirkpatrickExecutive Officer, Director
- Adam LevinDirector
- Curtis RosebraughDirector
- Steve MartinDirector
- William ChangDirector
- Bob GowerDirector
- Offering amount
- $15.9M
- Amount sold
- $5.3M
- Finders' fees
- $250K
- Placement agents
- Lake Street Capital Markets, LLC
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Robinhood16 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits15 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Simply Wall St15 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Seeking Alpha14 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingView14 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Companies competing with Ensysce Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Ensysce (NASDAQ: ENSC) raises $21M as it asks Nasdaq for time on $1 bid rulestocktitan.net · Aug 2026Frequently asked questions
- What does Ensysce Biosciences do?
- Ensysce is a pharmaceutical development company focused on developing safer medicines, with particular expertise in pain management and opioid-related drug development. The team has extensive experience bringing targeted small molecule drugs and oncology compounds from discovery through clinical development to market approval.
- Who founded Ensysce Biosciences?
- Ensysce Biosciences was founded by D. Lynn Kirkpatrick, PhD, Dr. Bob Gower.
- How much funding has Ensysce Biosciences raised?
- Ensysce Biosciences has disclosed $102.6M raised across 8 rounds.
- Where is Ensysce Biosciences headquartered?
- Ensysce Biosciences is headquartered in La Jolla, US.